Projects

International

• European Network for diagnosis and treatment of antibiotic-resistant bacterial infections
  Program: COST
  Duration: 6. 10. 2022 – 5. 10. 2026

• Multi-target paradigm for innovative ligand identification in the drug discovery process
  Program: COST
  Duration: 4. 12. 2015 – 29. 10. 2020

• Targeting Molecular Pathways of Glucolipotoxicity by a Novel Carboxymethylated Mercaptotriazinoindole Inhibitor of Aldo-Keto Reductase AKR1B1 In Diabetes, Inflammation and Age-related Neurodegeneration
  Program: Bilateral - other
  Duration: 1. 5. 2016 – 30. 4. 2019

• COST BM1204 : An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease
  Program: COST
  Duration: 16. 7. 2012 – 13. 12. 2016

• COST CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases
  Program: COST
  Duration: 28. 11. 2011 – 27. 11. 2015

National

• Molecular mechanisms implicated in corticosteroid-monoamine interaction in stress-related cardio- and neuropathologies
  Program: SRDA
  Duration: 1. 7. 2023 – 30. 6. 2027

• Ligand induced modulation of calcium pump SERCA – study of mechanism and design of new compounds
  Program: VEGA
  Duration: 1. 1. 2022 – 31. 12. 2026

• Development of multifunctional aldose reductase inhibitors based on triazinoindoles: Optimization of their biological activity, selectivity, bioavailability and antioxidant properties.
  Program: VEGA
  Duration: 1. 1. 2022 – 31. 12. 2025

• Multi-target approach to diverse molecular mechanisms of diabetic complications and other glucose toxicity related diseases
  Program: SRDA
  Duration: 1. 8. 2021 – 30. 6. 2025

• -
  Program: VEGA
  Duration: 1. 1. 2021 – 31. 12. 2024

• Development of products by modification of natural compounds and study of their multi-modal effects onCOVID-19 disease
  Program:
  Duration: 1. 7. 2021 – 30. 6. 2023

• Novel compounds in prevention and treatment of diseases caused by glucose toxicity
  Program: VEGA
  Duration: 1. 1. 2018 – 31. 12. 2021

• Pharmacological intervention in glucose-toxicity in type 2 diabetes
  Program: SRDA
  Duration: 1. 7. 2016 – 30. 6. 2020

• Multi-target paradigm for innovative ligand identification in the drug discovery process
  Program:
  Duration: 18. 4. 2016 – 17. 4. 2020

• Aldo-keto reductases in chronic diseases – in silico modeling of significant enzymes and their complexes with indole derivatives
  Program: VEGA
  Duration: 1. 1. 2014 – 31. 12. 2017

• MVTS An integrated European platform for pancreas cancer research: from basic science to clinical and public health interventions for a rare disease
  Program: Other projects
  Duration: 1. 6. 2013 – 13. 12. 2016

• CM1103 Structure-based drug design for diagnosis and treatment of neurological diseases
  Program: Other projects
  Duration: 1. 1. 2014 – 27. 11. 2015

• Substituted pyridoindoles as potential multi-target-directed ligands in prevention and treatment of chronic diseases - theoretical screening
  Program: VEGA
  Duration: 1. 1. 2011 – 31. 12. 2013

• IN SILICO, IN VITRO AND EX VIVO RESEARCH CONCERNING ANTI-INFECTIVE COMPOUNDS
  Program: SRDA
  Duration: 1. 1. 2011 – 31. 12. 2012

• Evaluation of activity parameters of potential inhibitors of aldose reductase – a contribution to therapy of chronic diabetic complications
  Program: VEGA
  Duration: 1. 1. 2007 – 1. 12. 2009

• Molecular mechanisms of new drugs influencing oxidative stress - important ethiopathogenetic factor of numerous diseases
  Program: SRDA
  Duration: 1. 9. 2006 – 31. 10. 2009

• Carboxymethylated pyridoindoles as inhibitors of aldose reductase with antioxidant activity: preclinical implicators for pharmacological prevention of diabetic complications
  Program: VEGA
  Duration: 1. 1. 2005 – 1. 12. 2007